Cancer Therapeutics: Cancer is often treated by surgery, chemotherapy, radiation therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy), hormonal therapy, and synthetic lethality. The choice of therapy depends upon the stage of the disease, and the location and grade of the tumor, as well as the patient's general status. Many clinical trial cancer treatments are also under development.
NCI estimates that cancer will be the leading cause of death in 2030, worldwide. Checkpoint inhibitors and adoptive cell therapies (ACTs) cost up to ~$2 million/patient and have shown durabl...
Learning Objectives: 1. Define applications of approved and experimental (multiplexing IF) biomarker assessment in Immuno-Oncology 2. Define bottlenecks and areas of improvement to current t...
B cells have recently come into vogue as important contributors to the anti-tumor immune response in cancer patients. Specifically, B cells and the immune structures in which they reside (te...
DATE: June 2, 2020 TIME: 7:00am PT, 10:00am ET In just a few months COVID-19 has risen from a regional crisis to a global threat, and drug makers are now scrambling to develop vaccines aimed...
DATE: May 27, 2020 TIME: 8:00am PT, 11:00am ET Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understand...
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently end...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Operational barriers like complicated workflows and long turnaround times have hindered broad adoption of next-generation sequencing (NGS) in clinical oncology research. The new Ion Torrent...
Learning Objectives: 1. Participants will become familiar with basic aspects of the user experience with the Genexus system 2. Participants will learn about preliminary studies using a targe...
Next-generation sequencing (NGS) has become the most effective tool in the practice of clinical oncology. The technology allows for rapid detection of variants in DNA/RNA simultaneously in a...
Next-generation sequencing (NGS) has become the most effective tool in the practice of clinical oncology. The technology allows for rapid detection of variants in DNA/RNA simultaneously in a...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
DATE: May 12, 2020 TIME: 8:00am PT Idiopathic aplastic anemia (AA) has two key characteristics: an autoimmune response against hematopoietic stem/progenitor cells and regulatory T cells (Tre...
NCI estimates that cancer will be the leading cause of death in 2030, worldwide. Checkpoint inhibitors and adoptive cell therapies (ACTs) cost up to ~$2 million/patient and have shown durabl...
Learning Objectives: 1. Define applications of approved and experimental (multiplexing IF) biomarker assessment in Immuno-Oncology 2. Define bottlenecks and areas of improvement to current t...
B cells have recently come into vogue as important contributors to the anti-tumor immune response in cancer patients. Specifically, B cells and the immune structures in which they reside (te...
DATE: June 2, 2020 TIME: 7:00am PT, 10:00am ET In just a few months COVID-19 has risen from a regional crisis to a global threat, and drug makers are now scrambling to develop vaccines aimed...
DATE: May 27, 2020 TIME: 8:00am PT, 11:00am ET Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understand...
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently end...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Operational barriers like complicated workflows and long turnaround times have hindered broad adoption of next-generation sequencing (NGS) in clinical oncology research. The new Ion Torrent...
Learning Objectives: 1. Participants will become familiar with basic aspects of the user experience with the Genexus system 2. Participants will learn about preliminary studies using a targe...
Next-generation sequencing (NGS) has become the most effective tool in the practice of clinical oncology. The technology allows for rapid detection of variants in DNA/RNA simultaneously in a...
Next-generation sequencing (NGS) has become the most effective tool in the practice of clinical oncology. The technology allows for rapid detection of variants in DNA/RNA simultaneously in a...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
DATE: May 12, 2020 TIME: 8:00am PT Idiopathic aplastic anemia (AA) has two key characteristics: an autoimmune response against hematopoietic stem/progenitor cells and regulatory T cells (Tre...
Follow
